ライフサイエンスコーパス: biguanide

1 nificantly lower than that induced by either biguanide.

2 Serine synthesis was not inhibited by biguanides.

3 K) is known to be a major cellular target of biguanides.

4 ga officinalis L.) led to the development of biguanides.

5 osphorylation are regulated independently by biguanides.

6 eated to determine whether polyhexamethylene biguanide, 0.02%, chlorhexidine digluconate, 0.02%, hexa

7 The structure-activity relationships of biguanides 5 and putative metabolites 8 are discussed.

8 vide a mechanism of tumor cell resistance to biguanide activity.

9 ed drugs (insulins, sulfonylureas, glinides, biguanides, alpha-glucosidase inhibitors, thiazolidinedi

10 We now report that novel biguanide and bisguanidine polyamine analogues are poten

11 s, C-fiber responses to injections of phenyl biguanide and lactic acid and to constant-pressure lung

12 ent, local irrigation with polyhexamethylene biguanide, and the systemic administration of voriconazo

13 , azines, amidines, guanidines, vinamidines, biguanides, and phosphazenes.

14 tions, synthetic lethality strategies, novel biguanides, and the use of predictive biomarkers.

15 We reported that (bis)guanidines, (bis)biguanides, and their urea- and thiourea isosteres are p

16 These defects predict sensitivity to biguanides, antidiabetic drugs that inhibit OXPHOS, when

17 ord and colleagues show, paradoxically, that biguanides are more effective in the treatment of mouse

18 anipulation that can enhance the efficacy of biguanides as antineoplastic agents that target cancer c

19 Polyhexamethylene biguanide can inhibit PCR, and we suggest that specimen

20 have investigated the effects of the diamino biguanide compound metformin and of hyperglycemia on MG

21 Bacillus subtilis , to develop guanidine and biguanide compounds with up to 20-fold increased potency

22 ese results suggest that cellular effects of biguanides depend on their metal-binding properties.

23 ed us to identify an anti-cancer drug of bis-biguanide dihydrochloride (BBD) as potent anti-mycobacte

24 The biguanide drug metformin has recently been found to impr

25 The biguanide drug metformin is widely prescribed to treat t

26 The biguanide drug metformin stimulates AMP-activated protei

27 Thiazolidinedione and biguanide drugs, which are used to increase insulin sens

28 r cell lines, the global metabolic impact of biguanides during the process of neoplastic transformati

29 Metformin, an insulin-sensitizing biguanide, enhances peripheral insulin action and lowers

30 Metformin (MF), a member of the biguanide group, has been shown to facilitate osteoblast

31 he delocalization of cationic charges in the biguanide groups of PolyMet reduces the toxicity of PEI

32 In contrast, in breast CSCs, biguanides have a modest effect on glycolytic and TCA cy

33 Despite of their plant origin, biguanides have not been reported in plants.

34 g) or the 5-HT(3) agonist l-(m-chlorophenyl)-biguanide hydrochloride (mCPBG; 5.0-15.0 mg/kg), alone o

35 Although phenformin is the more potent biguanide in both systems, the metabolic profiles of the

36 ddition, the possible biosynthetic routes of biguanide in these plant foods are discussed.

37 facilitate studies on metformin and related biguanides in cancer prevention and treatment.

38 d to increased interest in possible roles of biguanides in cancer prevention and/or treatment.

39 ular depletion of aPKC (>90%) led to loss in biguanide-induced aPKC phosphorylation, it had no effect

40 for serine to allow cells to compensate for biguanide-induced decrease in oxidative phosphorylation

41 ional PKCs caused a significant reduction in biguanide-induced GU.

42 Biguanide-induced inactivation of mTORC1 subsequently in

43 We demonstrate that biguanides inhibit growth by inhibiting mitochondrial re

44 c profiles are consistent with the idea that biguanides inhibit mitochondrial complex 1, but they ind

45 Metformin (MF), a second-generation biguanide, is a commonly used oral antidiabetic drug tha

46 tochondrial oxidative phosphorylation (using biguanides) led to a complex response that could improve

47 he 5-HT3 receptor agonist 1-m-(chlorophenyl) biguanide (m-CPGB, 1 microM), markedly increased (300%)

48 Biguanides may exploit specific metabolic vulnerabilitie

49 been proposed that this compound or related biguanides may have antineoplastic activity.

50 by the selective agonist 1-(m-chlorophenyl)-biguanide (mCPBG).

51 d the 5-HT3 receptor agonist, m-chlorophenyl-biguanide (mCPBG; 250, 500, or 1000 ng).

52 % [14 of 15 isolates]) and polyhexamethylene biguanide (median growth grade, 0.0; kill incidence rate

53 Biguanide/metal interactions are stabilized by extensive

54 CT1) affects the response to the widely used biguanide metformin (see the related article beginning o

55 onse to the sulphonylurea gliclazide and the biguanide metformin differed in HNF-1alpha diabetes and

56 The biguanide metformin had no effect on either enzyme, wher

57 In recent decades, the antihyperglycemic biguanide metformin has been used extensively in the tre

58 ion between TEA and Arg was found, while the biguanide metformin was able to strongly inhibit uptake

59 Use of the biguanide metformin, an AMPK activator, is associated wi

60 AMPK activators, including the antidiabetic biguanide metformin, inhibited FXR agonist induction of

61 The biguanide phenformin has been shown to independently dec

62 tabolic effects of metformin and the related biguanide phenformin have been investigated in establish

63 ation of the ERK inhibitor SCH772984 and the biguanide phenformin.

64 Met and its related biguanide, phenformin, stimulated AMPK activation/phosph

65 Polyhexamethylene biguanide (PHMB) is a disinfectant used in swimming pool

66 widely used antimicrobial polyhexamethylene biguanide (PHMB) kills bacteria selectively over host ce

67 lyethyleneimine (PEI) and poly(hexamethylene biguanide) (PHMBG) and are prepared by a two-step proced

68 f chemosensitive vagal afferents with phenyl biguanide produced an increase (n=3), decrease (n=2), or

69 A total of 34 analogues of the biguanide PS-15 (5s), a prodrug of the diaminotriazine W

70 The objective of this study was to quantify biguanide related compounds (BRCs) in experimentally or

71 Nonetheless, the mechanism of action of biguanides remains imperfectly understood.

72 Notably, the biguanide sensitivity of cancer cells with mtDNA mutatio

73 et-induced AMPK signaling but only repressed biguanide-stimulated GU by approximately 20%.

74 tineoplastic effects of phenformin (a potent biguanide structurally related to metformin).

75 ication of the metal-liganding groups of the biguanide structure, supporting recent data that AMPK an

76 Biguanides such as metformin are widely used worldwide f

77 Biguanides such as metformin have previously been shown

78 Biguanides, such as the diabetes therapeutics metformin

79 Biguanides, such as the diabetes therapeutics metformin

80 d pressure, statins adjusted for lipids, and biguanides, sulfonylureas, alpha-glycosidase inhibitors

81 kers, diuretics, nitrates, statins, insulin, biguanides, sulfonylureas, aspirin, and other nonsteroid

82 eported a series of (bis)guanidines and (bis)biguanides that are potent inhibitors of LSD1 and induce

83 and upregulation of ACAD10 are required for biguanides to reduce viability in melanoma and pancreati

84 vidence that this intrinsic property enables biguanides to regulate AMPK, glucose production, glucone

85 ring the process of cellular transformation, biguanide treatment prevents the boost in glycolytic int

86 anced the tumor growth-inhibitory actions of biguanide treatment.

87 Polyhexamethylene biguanide was the only topical drug that demonstrated PC

88 in reducing glucose production has been the biguanides, which include phenformin and metformin, the

89 Metformin is a biguanide widely prescribed to treat Type II diabetes th

90 Metformin, a biguanide widely used in the treatment of type II diabet